SCHEMBL6476396

SCHEMBL6476396

NC(=O)Nc1cccc2c1ccc1ccccc12

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.79
GAA P10253 2/20 0.79
ALDH1A1 P00352 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.55
POLB P06746 2/20 0.55
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
HPRT1 P00492 2/20 0.53
MAPT P10636 3/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
GRIN2D O15399 1/20 0.49
GRIN3B O60391 1/20 0.49
GRIN1 Q05586 1/20 0.49
GRIN2A Q12879 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL79802 0.89 KDM4E (1.00) KDM4EGAAALDH1A1SMN1; SMN2POLB
Hydrogen Sulfide SCHEMBL27471544 0.87 KDM4E (0.96) KDM4EGAAALDH1A1SMN1; SMN2POLB
SCHEMBL1567446 0.86 KDM4E (0.58) KDM4EGAAALDH1A1SMN1; SMN2POLB
SCHEMBL6476392 0.84 KDM4E (0.56) KDM4EGAAALDH1A1SMN1; SMN2POLB
SCHEMBL8982554 0.84 KDM4E (0.63) KDM4EGAAALDH1A1POLBNPC1
Trimethylammonium SCHEMBL27855504 0.82 KDM4E (0.86) KDM4EGAAALDH1A1SMN1; SMN2POLB
Piperazine SCHEMBL25235944 0.79 KDM4E (0.80) KDM4EGAAALDH1A1SMN1; SMN2POLB
SCHEMBL1269411 0.79 KDM4E (0.69) KDM4EGAARAB9AMAPTMEN1
SCHEMBL27931090 0.79 KDM4E (0.73) KDM4EGAAALDH1A1SMN1; SMN2POLB
SCHEMBL27933369 0.77 KDM4E (0.77) KDM4EGAAALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930114-B2 Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2005-08-16 US disclosed
US-20040138249-A1 Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-07-15 US disclosed
US-20030236276-A1 Pyrrolo[2.1-a]isoquinoline derivatives NIEWOHNER ULRICH (DE) 2003-12-25 US disclosed
EP-1347973-A1 PYRROLO (2.1-A) DIHYDROISOQUINOLINES AND THEIR USE AS PHOSPHODIESTERASE 10A INHIBITORS Bayer Aktiengesellschaft (DE) 2003-10-01 EP disclosed
WO-2003014117-A1 3-SUBSTITUTED PYRROLO[2.1-A]ISOQUINOLINE DERIVATIVES BAYER CORPORATION (US) 2003-02-20 WO disclosed
WO-2003014116-A1 PYRROLO[2.1-A]ISOQUINOLINE DERIVATIVES BAYER CORPORATION (US) 2003-02-20 WO disclosed
WO-2002048144-A1 PYRROLO (2.1-A) DIHYDROISOQUINOLINES AND THEIR USE AS PHOSPHODIESTERASE 10A INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236276-A1 Pyrrolo[2.1-a]isoquinoline derivatives PDE5A, PDE2A, PDE3A KDM4E 1821/4885GAA 904/4885ALDH1A1 162/4885
US-20040138249-A1 Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors PDE7B, PDE2A, PDE5A KDM4E 714/4885GAA 1560/4885ALDH1A1 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.